Structure Therapeutics annual return on equity
2023
2024
2025
Structure Therapeutics Return on Equity (ROE) Growth & History (GPCR)
Structure Therapeutics's return on equity was −11.86% for fiscal 2025.
View full Structure Therapeutics company overviewStructure Therapeutics annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −11.86% | +6.74 pp |
| 2024 | 2024-12-31 | −18.60% | +34.46 pp |
| 2023 | 2023-12-31 | −53.06% | — |
Structure Therapeutics quarterly return on equity
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −7.58% | +0.14 pp |
| Q1 2026 | 2026-03-31 | −5.13% | +0.42 pp |
| Q4 2025 | 2025-12-31 | 2.89% | +7.03 pp |
| Q3 2025 | 2025-09-30 | −8.52% | −4.78 pp |
| Q2 2025 | 2025-06-30 | −7.72% | −3.87 pp |
| Q1 2025 | 2025-03-31 | −5.54% | +0.35 pp |
| Q4 2024 | 2024-12-31 | −4.14% | +3.45 pp |
| Q3 2024 | 2024-09-30 | −3.74% | +7.98 pp |
| Q2 2024 | 2024-06-30 | −3.85% | +6.47 pp |
| Q1 2024 | 2024-03-31 | −5.90% | +23.76 pp |
| Q4 2023 | 2023-12-31 | −7.59% | — |
| Q3 2023 | 2023-09-30 | −11.71% | — |
| Q2 2023 | 2023-06-30 | −10.33% | — |
| Q1 2023 | 2023-03-31 | −29.66% | — |
Structure Therapeutics return on equity trends
Between the periods ended 2023-12-31 and 2025-12-31, Structure Therapeutics's return on equity increased from −53.06% to −11.86%, a change of +41.20 percentage points. The latest reported quarter, Q2 2026, shows −7.58%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Structure Therapeutics source filings ↗Community posts
Structure reports up to 16.2% weight loss in extended obesity study
Structure Therapeutics ($GPCR) reported up to 16.2% average body-weight reduction at 72 weeks in an open-label extension study of aleniglipron, its experimental oral GLP-1 treatment. Participants in the highest-performing group had escalate ...